Início › Câncer de Mama › Pensilvânia › Philadelphia
Ensaios clínicos de Câncer de Mama em Philadelphia, PA
56 estudos para Câncer de Mama estão buscando participantes em locais em Philadelphia e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecrutandoFase 1/2
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
RecrutandoFase 3
- Consultants In Med Onco And Hema, Drexel Hill · a 7 mi de distância
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
- Reading Hospital McGlinn Cancer Institute at Phoenixville, Phoenixville · a 22 mi de distância
A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer
RecrutandoFase 2
- University of Pennsylvania, Abramson Cancer Center, Perelman Center for Advanced Medicine, Philadelphia
- Alliance Cancer Specialists, Horsham · a 16 mi de distância
Study of AVZO-021 in Patients With Advanced Solid Tumors
RecrutandoFase 1/2
- Avenzo Therapeutics Recruiting Site, Philadelphia
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
RecrutandoFase 3
- Thomas Jefferson University - Clinical Research Institute ( Site 0056), Philadelphia
The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study
RecrutandoFase 3
- Penn Medicine - Perelman Center for Advanced Medicine, Philadelphia
- Penn Medicine - Chester County Hospital, West Chester · a 24 mi de distância
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
RecrutandoFase 3
- Clinical Trial Site, Horsham · a 16 mi de distância
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
RecrutandoFase 1
- University of Pennsylvania, Philadelphia
- Fox Chase Cancer Center, Philadelphia
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
RecrutandoFase 3
- University of Pennsylvania Hospital, Philadelphia
- Thomas Jefferson University - Clinical Research Institute, Philadelphia
- Jefferson Hospital Northeast, Philadelphia
- e mais 1
Evolutionary Clinical Trial for Novel Biomarker-Driven Therapies
RecrutandoFase 2
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
RecrutandoFase 3
- Fox Chase Cancer Center, Philadelphia
- Lankenau Medical Center, Wynnewood · a 7 mi de distância
- Consultants In Medical Oncology and Hematology, P.C., Broomall · a 10 mi de distância
- e mais 1
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
RecrutandoFase 1/2
- University of Pennsylvania - Abramson Cancer Center, Philadelphia
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
RecrutandoFase 1/2
- University of Pennsylvania, Philadelphia
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
RecrutandoFase 1
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
RecrutandoEstudo observacional
- Abramson Cancer Center, Philadelphia
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
RecrutandoFase 3
- University of Pennsylvania/Abramson Cancer Center, Philadelphia
- Thomas Jefferson University Hospital, Philadelphia
- Fox Chase Cancer Center, Philadelphia
- e mais 11
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
RecrutandoFase 1
- Sidney Kimmel Comprehensive Center at Jefferson, Philadelphia
PENN-Surveillance Markers of Utility for Recurrence After (Neo)Adjuvant Therapy for Breast Cancer
Recrutando
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
ATEMPT 2.0: Adjuvant T-DM1 vs TH
RecrutandoFase 2
- University of Pennsylvania, Abramson Cancer Center, Philadelphia
Tai Chi for Reducing Aromatase Inhibitor-Induced Arthralgia
Recrutando
- Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
RecrutandoFase 2/3
- Abramson Cancer Center of The University of Pennsylvania, Philadelphia
Axillary Radiotherapy or Axillary Lymph Node Dissection in Patients With Clinically Node- Positive Breast Cancer Undergoing Upfront Tailored Axillary Surgery
Recrutando
- Fox Chase Cancer Center, Philadelphia
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
RecrutandoFase 3
- Sidney Kimmel Comprehensive Cancer Center - Thomas Jefferson University Hospital, Philadelphia
E-Mindfulness Approaches for Living After Breast Cancer
RecrutandoFase 3
- UPMC Hillman Cancer Center - Part of Frick Hospital, Mount Pleasant · a 8 mi de distância
- Chester County Hospital, West Chester · a 24 mi de distância
Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
RecrutandoVoluntários saudáveis bem-vindos
- Thomas Jefferson University Hospital, Philadelphia
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
RecrutandoFase 2
- Thomas Jefferson University, Philadelphia
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RecrutandoFase 1
- Investigative Site #109, Philadelphia
Virtual Mindful After Cancer (MAC) Intervention to Promote Sexual Health for Breast and Gynecologic Cancer Survivors
RecrutandoFase 1
- University of Pennsylvania, Philadelphia
- Fox Chase Cancer Center, Philadelphia
A Mixed-Methods Metabolomics Investigation of Lifestyle and Energy Balance During Breast Cancer Survivorship
Recrutando
- Abamson Cancer Center of the University of Pennsylvania, Philadelphia
ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer
RecrutandoFase 2
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
RecrutandoFase 3
- Rittenhouse Hematology/Oncology, Philadelphia
Identification of Breast Cancer in Breath Samples Using Trained Detection Dogs
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
- Hospital of the University of Pennsylvania, Philadelphia
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RecrutandoFase 2
- University of Pennsylvania (U Penn), Philadelphia
Window Study of Intratumoral Mitazalimab in Breast Cancer (WINIT-BC)
RecrutandoFase 1 inicial
- Hospital of the University of Pennsylvania, Philadelphia
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
RecrutandoFase 2
- University of Pennsylvania-Abramson Cancer Center, Philadelphia
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
RecrutandoFase 2
- University of Pennsylvania-Abramson Cancer Center, Philadelphia
B.Brilliant Revelation Comparision Study
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
- Pennsylvania Hospital, Center for Breast Imaging, Philadelphia
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
RecrutandoFase 3
- Thomas Jefferson University Hospital, Philadelphia
- Fox Chase Cancer Center, Philadelphia
- Jefferson Torresdale Hospital, Philadelphia
- e mais 4
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
RecrutandoFase 1
- University of Pennsylvania, Philadelphia
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
RecrutandoFase 2
- University of Pennsylvania, Philadelphia
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
RecrutandoFase 1/2
- Thomas Jefferson University, Sidney Kimmel Comprehensive Cancer Center, Philadelphia
EXploring Inflammation and Social deTerminants Study in Breast Cancer Patients
RecrutandoEstudo observacional
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, Philadelphia
FES BPET-DBT in Newly Diagnosed Breast Cancer
RecrutandoFase 1 inicial
- University of Pennsylvania, Philadelphia
Safe and Explainable AI
RecrutandoEstudo observacional
- Hospital of the University of Pennsylvania, Philadelphia
A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
RecrutandoFase 1
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
- Fox Chase Cancer Center, Philadelphia
CTNNA1 Familial Expansion Study
RecrutandoEstudo observacional
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
RecrutandoFase 4
- Albert Einstein Healthcare Network, Philadelphia
[18F] F-GLN by PET/CT in Breast Cancer
RecrutandoFase 1
- University of Pennsylvania, Philadelphia
Prospective Breast Cancer Biospecimen Collection
RecrutandoEstudo observacional
- Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia
Targeted Palliative Care Intervention for Patients With Metastatic Breast Cancer
Recrutando
- University of Pennsylvania, Philadelphia
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
RecrutandoEstudo observacional
- Massive Bio SYNERGY-AI site, Philadelphia
Surviving Daily Life
RecrutandoEstudo observacional
- Thomas Jefferson University, Philadelphia
The Cancer of the Pancreas Screening-5 CAPS5)Study
RecrutandoFase 3
- University of Pennsylvania, Philadelphia
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
RecrutandoEstudo observacional
- Consultants in Medical Oncology and Hematology, P.C., Broomall · a 10 mi de distância
- Alliance Cancer Specialists, Horsham · a 16 mi de distância
Role of the Immune Environment in Response to Therapy in Breast Cancer
RecrutandoEstudo observacional
- Abramson Cancer Center, Philadelphia
Ensaios de Câncer de Mama em outras cidades
- New York City, NY136 estudos
- Houston, TX126 estudos
- Boston, MA112 estudos
- Nashville, TN81 estudos
- Los Angeles, CA73 estudos
- Edison, NJ68 estudos
- St. Louis, MO64 estudos
- Queens, NY64 estudos
- Durham, NC64 estudos
- Chicago, IL59 estudos
- Dallas, TX55 estudos
- Arlington, VA47 estudos
Outros estudos em Philadelphia
- Câncer (todos os tipos)59 estudos
- Câncer de Pulmão de Não Pequenas Células51 estudos
- Câncer Metastático46 estudos
- Câncer de Próstata44 estudos
- Câncer Colorretal44 estudos
- Câncer de Ovário44 estudos
- Câncer de Pulmão36 estudos
- Leucemia Mieloide Aguda34 estudos
- Insuficiência Cardíaca31 estudos
- Câncer Endometrial28 estudos
- Depressão26 estudos
- Câncer de Pâncreas26 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 6 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.